TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in Cardiac Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Cardiac Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Mean Pulmonary Arterial Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tooth mobility (Miller classification)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periapical lesion occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Root resorption occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive percent agreement (PPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Negative percent agreement (NPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total lymph volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modified Roland Morris Disability Questionnaire for back pain-specific disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Correction of skeletal Class II profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of successful immunosuppressive drug withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrahepatic Disease-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Documented Recurrence of Atrial Fibrillation/Atrial Flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cure rate of recurrent corneal erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of pain relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: LRRK2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in OAB-q Symptom Bother Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Volume of Residual Enhancing Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of S. aureus ICU pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of P. aeruginosa ICU pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients in Each Group at Predefined Target TSH Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Mean PTH ≤ 300 pg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Biopsy-proven Acute Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Off-label Use of Olodaterol Among New Users
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: satisfactory sexual events
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in intervention effect of adjuvant treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of virological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of drug resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete remission with incomplete recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on tension headache severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Virological Transmission by Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Events (>10%)
Endpoint domain: Adverse events/effects
Primary endpoint: Best Overall Tumor Response Based on RECIST V1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Thompson articular index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentual change in serum LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute change in serum LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptomatic venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum postprandial blood glucose added value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood glucose AUC in different periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects with adverse events as assessed by CTCAE V5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Dental Plaque Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Tumor Proliferative Index using Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Unscheduled Return to Clinic or Emergency Room
Endpoint domain: Adverse events/effects
Primary endpoint: Median Visual Analog Pain (VAS) Pain Scale Experienced by Participant 24 Hours Following Stent Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Pain (VAS) Pain Scale 7 Days Following Stent Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive performance as measured by HVLT
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With High Grade (Grade 3-4) Immune Mediated Adverse Events (IMAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With High Grade (Grade 5) Immune Mediated Adverse Events (IMAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Generalized Anxiety Disorder Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Extubation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Stay in the PACU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Skeletal muscle function by isokinetic dynamometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of hypoxia-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inspiratory capacity (IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quit Attempts
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Use of NRTs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Preference Among NRTs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decreased asthma hospitalization rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Concentrations Against Glycoprotein E (Anti-gE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Concentrations Against Diphteria (Anti-D) and Tetanus (Anti-T) Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of new driving impairments
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maternal Sleep Quantity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Infant Sleep Quantity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: General Self-Efficacy Scale (GSE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean corneal fluorescein staining (inferior region)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ocular discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cardiac parameters using 12-lead ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pulmonary parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: American Orthopedic Foot and Ankle Society (AOFAS) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Partial Thromboplastin Time (PTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reported Subject Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: General Cardiovascular Risk Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lipids (total cholesterol, triglycerides HDL-C, LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Discontinuation of Glucophage XR treatment due to side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Human Papillomavirus Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diuretic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients committing rudeness/incivility or aggression
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Standardized Uptake Values (SUVs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Volume of ROI for Each Organ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of sonidegib in combination with pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of sonidegib in combination with pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic UTI
Endpoint domain: Adverse events/effects
Primary endpoint: Pupil response measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ADL ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of Apnea Hypopnea Index > 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Modified shuttle walk test (MSWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients experiencing at least one Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Cervical Tissue Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical PET type assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of neck joint-position error between different weight conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of neck joint-position error between two sitting positions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of neck range of motion between different weight conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of spinal stiffness between different sitting positions and loading conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication rate after second line treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ETDRS visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HIV-1 Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of high-risk individuals assessed for cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of individuals with correct knowledge about behavioural determinants of cardiovascular disease risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reading ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Speed of Information Processing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Executive Functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stool composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Laboratory-confirmed episode of severe rotavirus gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients who complete sleep testing
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Detection of circulating cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Control Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operator's time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Residual Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient oriented composite endpoint (PoCE)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to dementia onset
Endpoint domain: Mortality/survival
Primary endpoint: Type 2 diabetes remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognigram score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Detection of known type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cigarette choice behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall safety and tolerability measured by Adverse Event (AE) recording
Endpoint domain: Adverse events/effects
Primary endpoint: Long term incidence of malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: post operative myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change at Depression subscale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change at Anxiety subscale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Length of Hospitalization Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pain evaluation during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Moderate to Vigorous Physical Activity (MVPA) Average Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuation rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetic analysis of simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic analysis of carvedilol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treadmill Exercise Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cancers identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of false positive findings
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Infection of Vector Mosquitoes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Coracohumeral ligament thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue composition of the rotator interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascularity in the rotator interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Participants With at Least One Serious Adverse Event (SAE) Throughout the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 1
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 2
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 3
Endpoint domain: Adverse events/effects
Primary endpoint: Failure-free survival at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Interstitial levels of adenosine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 Year Disease-free survival (DFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: 5-km Running Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid Peroxides (TBARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients Achieving a Physician's Global Assessment of Clear or Almost Clear
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Recurrent stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Levels of catecholamines in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FceRI Positive Skin Cells Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgE Positive Skin Cells Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety profile of ZD 1839
Endpoint domain: Adverse events/effects
Primary endpoint: reduction of CDAI by 70 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family caregiver quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Family caregiver grief symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Single nucleotide polymorphisms (SNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erect penis length and girth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of DC Vaccines with Nivolumab
Endpoint domain: Adverse events/effects
Primary endpoint: No further progression toward infection (bioburden)
Endpoint domain: Adverse events/effects
Primary endpoint: Ease of application and removal
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percent progression to closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Wound healing outcomes
Primary endpoint: total dose of rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of metabolic acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDAC and HAT activity ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Cardiac Event (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: Ischemia Driven Target Lesion Revascularisation (ID-TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with clear tissue characteristics of skin diseases and/or normal skin in tomograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of subjects with the distinction between skin lesion and normal skin in tomograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Endothelial Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Retina Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Catheter related bladder discomfort symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive urinary culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Acute toxicity rates of grade 3 gastrointestinal toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acute toxicity rates of grade 3 hematologic toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: First incident pulmonary embolism
Endpoint domain: Mortality/survival